Blocking NS3-NS4B interaction inhibits dengue virus in non-human primates.
Animals
Humans
Mice
Antiviral Agents
/ adverse effects
Dengue
/ drug therapy
Dengue Virus
/ classification
Primates
/ virology
Viral Nonstructural Proteins
/ antagonists & inhibitors
Virus Replication
Protein Binding
/ drug effects
Molecular Targeted Therapy
In Vitro Techniques
Dose-Response Relationship, Drug
Drug Resistance, Viral
Clinical Trials, Phase I as Topic
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
29
06
2022
accepted:
03
02
2023
pubmed:
17
3
2023
medline:
25
3
2023
entrez:
16
3
2023
Statut:
ppublish
Résumé
Dengue is a major health threat and the number of symptomatic infections caused by the four dengue serotypes is estimated to be 96 million
Identifiants
pubmed: 36922586
doi: 10.1038/s41586-023-05790-6
pii: 10.1038/s41586-023-05790-6
pmc: PMC10033419
doi:
Substances chimiques
Antiviral Agents
0
Viral Nonstructural Proteins
0
NS3 protein, flavivirus
0
NS4B protein, Dengue virus
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
678-686Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201700040I
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023. The Author(s).
Références
Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504–507 (2013).
pubmed: 23563266
pmcid: 3651993
doi: 10.1038/nature12060
Stanaway, J. D. et al. The global burden of dengue: an analysis from the global burden of disease study 2013. Lancet Infect. Dis. 16, 712–723 (2016).
pubmed: 26874619
pmcid: 5012511
doi: 10.1016/S1473-3099(16)00026-8
Kaptein, S. J. F. et al. A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction. Nature 598, 504–509 (2021).
pubmed: 34616043
doi: 10.1038/s41586-021-03990-6
Ackaert, O. et al. Safety, tolerability and pharmacokinetics of a novel pan-serotype dengue antiviral small molecule in a phase 1, double-blind, randomized, dose-escalation study [abstract 0582]. in The American Society of Tropical Medicine & Hygiene (ASTMH) Virtual Meeting Abstract Book (2021).
Zeng, W., Halasa-Rappel, Y. A., Durand, L., Coudeville, L. & Shepard, D. S. Impact of a nonfatal dengue episode on disability-adjusted life years: a systematic analysis. Am. J. Trop. Med. Hyg. 99, 1458–1465 (2018).
pubmed: 30277202
pmcid: 6283510
doi: 10.4269/ajtmh.18-0309
Global Strategy for Dengue Prevention and Control, 2012–2020 (WHO, 2012); http://apps.who.int/iris/bitstream/10665/75303/1/9789241504034_eng.pdf?ua=1
Ebi, K. L. & Nealon, J. Dengue in a changing climate. Environ. Res. 151, 115–123 (2016).
pubmed: 27475051
doi: 10.1016/j.envres.2016.07.026
Gubler, D. J. Dengue, urbanization and globalization: the unholy trinity of the 21
pubmed: 22500131
pmcid: 3317603
doi: 10.2149/tmh.2011-S05
Messina, J. P. et al. The current and future global distribution and population at risk of dengue. Nat. Microbiol. 4, 1508–1515 (2019).
pubmed: 31182801
pmcid: 6784886
doi: 10.1038/s41564-019-0476-8
Ong, A., Sandar, M., Chen, M. I. & Sin, L. Y. Fatal dengue hemorrhagic fever in adults during a dengue epidemic in Singapore. Int. J. Infect. Dis. 11, 263–267 (2007).
pubmed: 16899384
doi: 10.1016/j.ijid.2006.02.012
Halstead, S. B. Dengue. Lancet 370, 1644–1652 (2007).
pubmed: 17993365
doi: 10.1016/S0140-6736(07)61687-0
Katzelnick, L. C. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 358, 929–932 (2017).
pubmed: 29097492
pmcid: 5858873
doi: 10.1126/science.aan6836
Thomas, S. J. & Yoon, I.-K. A review of Dengvaxia®: development to deployment. Hum. Vaccin. Immunother. 15, 2295–2314 (2019).
pubmed: 31589551
pmcid: 6816420
doi: 10.1080/21645515.2019.1658503
Wilder-Smith, A. The first licensed dengue vaccine: can it be used in travelers? Curr. Opin. Infect. Dis. 32, 394–400 (2019).
pubmed: 31305495
doi: 10.1097/QCO.0000000000000573
Fongwen, N. et al. Target product profile for a dengue pre-vaccination screening test. PLoS Negl. Trop. Dis. 15, e0009557 (2021).
pubmed: 34324505
pmcid: 8320982
doi: 10.1371/journal.pntd.0009557
[No authors listed.] Dengue vaccine: WHO position paper, September 2018—recommendations. Vaccine 37, 4848–4849 (2019).
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure (Takeda, 2022); https://www.takeda.com/newsroom/newsreleases/2022/takedas-qdenga-dengue-tetravalent-vaccine-live-attenuated-approved-in-indonesia-for-use-regardless-of-prior-dengue-exposure/ .
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union (Takeda, 2022); https://www.takeda.com/newsroom/newsreleases/2022/takedas-qdenga-dengue-tetravalent-vaccine-live-attenuated-approved-for-use-in-european-union/ .
Takeda UK Ltd. announces MHRA approval for dengue virus vaccine candidate Qdenga®▼ (Bloomberg, 2023); https://www.bloomberg.com/press-releases/2023-02-06/takeda-uk-ltd-announces-mhra-approval-for-dengue-virus-vaccine-candidate-qdenga .
Low, J. G., Gatsinga, R., Vasudevan, S. G. & Sampath, A. Dengue antiviral development: a continuing journey. Adv. Exp. Med. Biol. 1062, 319–332 (2018).
pubmed: 29845542
doi: 10.1007/978-981-10-8727-1_22
Whitehorn, J. et al. Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions. PLoS Negl. Trop. Dis. 8, e3025 (2014).
pubmed: 25166493
pmcid: 4148227
doi: 10.1371/journal.pntd.0003025
Kou, Z. et al. Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J. Med. Virol. 80, 134–146 (2008).
pubmed: 18041019
doi: 10.1002/jmv.21051
Touret, F. et al. Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery. Antiviral Res. 168, 109–113 (2019).
pubmed: 31085207
doi: 10.1016/j.antiviral.2019.05.005
Williams, K. L., Zompi, S., Beatty, P. R. & Harris, E. A mouse model for studying dengue virus pathogenesis and immune response. Ann. N. Y. Acad. Sci. 1171, E12–E23 (2009).
pubmed: 19751398
doi: 10.1111/j.1749-6632.2009.05057.x
Hsu, A. et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47, 350–359 (2003).
pubmed: 12499212
pmcid: 148953
doi: 10.1128/AAC.47.1.350-359.2003
Gatti, G. et al. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children. Clin. Infect. Dis. 36, 1476–1482 (2003).
pubmed: 12766843
doi: 10.1086/375062
Mo, H. et al. Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors. J. Viral Hepat. 18, 338–348 (2011).
pubmed: 20456634
doi: 10.1111/j.1365-2893.2010.01314.x
Herrmann, E. et al. Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor Biln 2061. Antivir. Ther. 11, 371–376 (2005).
doi: 10.1177/135965350601100303
Norshidah, H., Vignesh, R. & Lai, N. S. Updates on dengue vaccine and antiviral: where are we heading? Molecules 26, 6768 (2021).
pubmed: 34833860
pmcid: 8620506
doi: 10.3390/molecules26226768
Guzman, M. G. & Harris, E. Dengue. Lancet 385, 453–465 (2015).
pubmed: 25230594
doi: 10.1016/S0140-6736(14)60572-9
Wang, Q.-Y. et al. Discovery of dengue virus NS4B inhibitors. J. Virol. 89, 8233–8244 (2015).
pubmed: 26018165
pmcid: 4524232
doi: 10.1128/JVI.00855-15
Xie, X., Zou, J., Wang, Q. Y. & Shi, P. Y. Targeting dengue virus NS4B protein for drug discovery. Antiviral Res. 118, 39–45 (2015).
pubmed: 25796970
doi: 10.1016/j.antiviral.2015.03.007
Hernandez-Morales, I. et al. Characterization of a dengue NS4B inhibitor originating from an HCV small molecule library. Antiviral Res. 147, 149–158 (2017).
pubmed: 29037976
doi: 10.1016/j.antiviral.2017.10.011
Wilder-Smith, A. Dengue vaccine development: status and future. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 63, 40–44 (2020).
pubmed: 31784763
doi: 10.1007/s00103-019-03060-3
Agudelo Higuita, N. I., White, B. P., Franco-Paredes, C. & McGhee, M. A. An update on prevention of malaria in travelers. Ther. Adv. Infect. Dis. 8, 20499361211040690 (2021).
pubmed: 34484736
pmcid: 8408895
Nakato, H., Vivancos, R. & Hunter, P. R. A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria. J. Antimicrob. Chemother. 60, 929–936 (2007).
pubmed: 17848375
doi: 10.1093/jac/dkm337
Straubinger, T., Kay, K. & Bies, R. Modeling HIV pre-exposure prophylaxis. Front. Pharmacol. 10, 1514 (2019).
pubmed: 32082142
doi: 10.3389/fphar.2019.01514
Orr, H. A. & Unckless, R. L. The population genetics of evolutionary rescue. PLoS Genet. 10, e1004551 (2014).
pubmed: 25121960
pmcid: 4133041
doi: 10.1371/journal.pgen.1004551
Nguyen, N. M. et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J. Infect. Dis. 207, 1442–1450 (2013).
pubmed: 22807519
doi: 10.1093/infdis/jis470
Waickman, A. T. et al. Evolution of inflammation and immunity in a dengue virus 1 human infection model. Sci. Transl. Med. 14, eabo5019 (2022).
Raafat, N., Blacksell, S. D. & Maude, R. J. A review of dengue diagnostics and implications for surveillance and control. Trans. R. Soc. Trop. Med. Hyg. 113, 653–660 (2019).
pubmed: 31365115
pmcid: 6836713
doi: 10.1093/trstmh/trz068
Vaughn, D. W. et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181, 2–9 (2000).
pubmed: 10608744
doi: 10.1086/315215
Libraty, D. H. et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J. Infect. Dis. 186, 1165–1168 (2002).
pubmed: 12355369
doi: 10.1086/343813
Murgue, B., Roche, C., Chungue, E. & Deparis, X. Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia. J. Med. Virol. 60, 432–438 (2000).
pubmed: 10686027
doi: 10.1002/(SICI)1096-9071(200004)60:4<432::AID-JMV11>3.0.CO;2-7
Busch, M. P. et al. Duration of dengue viremia in blood donors and relationships between donor viremia, infection incidence and clinical case reports during a large epidemic. J. Infect. Dis. 214, 49–54 (2016).
pubmed: 27302934
pmcid: 4907419
doi: 10.1093/infdis/jiw122
Le Pogam, S. et al. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J. Virol. 80, 6146–6154 (2006).
pubmed: 16731953
pmcid: 1472602
doi: 10.1128/JVI.02628-05
Thompson, A. J., Locarnini, S. A. & Beard, M. R. Resistance to anti-HCV protease inhibitors. Curr. Opin. Virol. 1, 599–606 (2011).
pubmed: 22440917
doi: 10.1016/j.coviro.2011.10.001
Liu, T., Sun, Q., Gu, J., Cen, S. & Zhang, Q. Characterization of the tenofovir resistance-associated mutations in the hepatitis B virus isolates across genotypes A to D. Antiviral Res. 203, 105348 (2022).
pubmed: 35644506
doi: 10.1016/j.antiviral.2022.105348
Kayesh, M. E. H. & Tsukiyama-Kohara, K. Mammalian animal models for dengue virus infection: a recent overview. Arch. Virol. 167, 31–44 (2022).
pubmed: 34761286
doi: 10.1007/s00705-021-05298-2
Miller, S., Sparacio, S. & Bartenschlager, R. Subcellular localization and membrane topology of the dengue virus type 2 non-structural protein 4B. J. Biol. Chem. 281, 8854–8863 (2006).
pubmed: 16436383
doi: 10.1074/jbc.M512697200
Zmurko, J., Neyts, J. & Dallmeier, K. Flaviviral NS4b, chameleon and jack-in-the-box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention. Rev. Med. Virol. 25, 205–223 (2015).
pubmed: 25828437
pmcid: 4864441
doi: 10.1002/rmv.1835
Chatel-Chaix, L. et al. A combined genetic-proteomic approach identifies residues within dengue virus NS4B critical for interaction with NS3 and viral replication. J. Virol. 89, 7170–7186 (2015).
pubmed: 25926641
pmcid: 4473547
doi: 10.1128/JVI.00867-15
Fischl, W. & Bartenschlager, R. High-throughput screening using dengue virus reporter genomes. Methods Mol. Biol. 1030, 205–219 (2013).
pubmed: 23821271
doi: 10.1007/978-1-62703-484-5_17
Endy, T. P. et al. A phase 1, open-label assessment of a dengue virus-1 live virus human challenge strain. J. Infect. Dis. 223, 258–267 (2021).
pubmed: 32572470
doi: 10.1093/infdis/jiaa351
Milligan, G. N. et al. Spectrum of activity testing for therapeutics against all four dengue virus serotypes in AG129 mouse models: proof-of-concept studies with the adenosine nucleoside inhibitor NITD-008. Antiviral Res. 154, 104–109 (2018).
pubmed: 29665374
pmcid: 6685202
doi: 10.1016/j.antiviral.2018.04.012
Gong, E. Y. et al. Cell-based antiviral assays for screening and profiling inhibitors against dengue virus. Methods Mol. Biol. 1030, 185–194 (2013).
pubmed: 23821269
doi: 10.1007/978-1-62703-484-5_15
Kaptein, S. J. et al. A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro. Antimicrob. Agents Chemother. 54, 5269–5280 (2010).
pubmed: 20837762
pmcid: 2981273
doi: 10.1128/AAC.00686-10
De Burghgraeve, T. et al. An analogue of the antibiotic teicoplanin prevents flavivirus entry in vitro. PLoS ONE 7, e37244 (2012).
pubmed: 22624001
pmcid: 3356272
doi: 10.1371/journal.pone.0037244
Santiago, G. A. et al. Analytical and clinical performance of the CDC real time RT-PCR assay for detection and typing of dengue virus. PLoS Negl. Trop. Dis. 7, e2311 (2013).
pubmed: 23875046
pmcid: 3708876
doi: 10.1371/journal.pntd.0002311
Kato, F. et al. Natural infection of cynomolgus monkeys with dengue virus occurs in epidemic cycles in the Philippines. J. Gen. Virol. 94, 2202–2207 (2013).
pubmed: 23851439
doi: 10.1099/vir.0.055343-0
Kärber, G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmakol. 162, 480–483 (1931).
doi: 10.1007/BF01863914
Spearman, C. The method of “right and wrong cases” (constant stimuli) without Gauss’s formula. Br. J. Psychol. 2, 227–242 (1908).
Sadon, N. et al. A new quantitative RT-PCR method for sensitive detection of dengue virus in serum samples. J. Virol. Methods 153, 1–6 (2008).
pubmed: 18652847
doi: 10.1016/j.jviromet.2008.06.023
Klungthong, C. et al. Monitoring and improving the sensitivity of dengue nested RT-PCR used in longitudinal surveillance in Thailand. J. Clin. Virol. 63, 25–31 (2015).
pubmed: 25600599
doi: 10.1016/j.jcv.2014.12.009
Jaki, T. & Wolfsegger, M. J. Estimation of pharmacokinetic parameters with the R package PK. Pharm. Stat. 10, 284–288 (2011).
doi: 10.1002/pst.449
Verbist, B. M. et al. VirVarSeq: a low-frequency virus variant detection pipeline for Illumina sequencing using adaptive base-calling accuracy filtering. Bioinformatics 31, 94–101 (2015).
pubmed: 25178459
doi: 10.1093/bioinformatics/btu587